紫杉醇联合顺铂治疗晚期非小细胞肺癌46例的临床观察

Paclitaxel combined with cisplatin for treatment of advanced non-small cell lung cancer: Clinical observation of 46 cases

目的观察国产紫杉醇联合顺铂治疗Ⅲ～Ⅳ期非小细胞肺癌(NSCLC)的近期疗效和毒副反应。方法选Ⅲ～Ⅳ期NSCLC病例46例,用紫杉醇150 mg/m^2加入5%葡萄糖注射液500ml中静脉滴注3h,d_1,顺铂60 mg加入生理盐水注射液100 ml中静脉滴注,d_(2、3),3～4周为1周期,2～5周期后评价疗效。结果全组46例有效率为39.13%(18/46),主要毒副反应为血液毒性反应、脱发及消化道反应。结论紫杉醇联合顺铂治疗晚期NSCLC有较好疗效,毒副反应较小,可以耐受。

Objective To observe short-term efficacy and toxicity of paclitaxel and cisplatin in the treatment of Ⅲ～Ⅳ non-small cell lung cancer. Methods Forty-six cases of Ⅲ～Ⅳ non-small cell lung cancer were treared by intravenous drip of paclitaxel 150 mg/m^2 in 5% glucose injection 500 ml, within 3 hours, d1 ; cisplatin 60 rag in 100 ml normal saline injection, intravenous drip, d2,3. A cycle lasted for 3 to 4 weeks. After 2 to 5 cycles the treatment effects were evaluated. Results In Forty-six cases the response rate was 39. 13% （18/46）. The main toxicities inclnded blood toxicity, alopecia, and digestive tract reaction. Conclusion Paclitaxel combined with cisplatin for treatment of advanced non-small cell lung cancer have better efficacy, less toxicity and can be tolerated.